Statement: the primary trial and the secondary trial observed a different number of adverse events in their patients.
Primary_evidence: Adverse Events 1:   Total: 25/60 (41.67%)   Anaemia * 1/60 (1.67%)   Febrile neutropenia * 2/60 (3.33%)   Idiopathic thrombocytopenic purpura * 1/60 (1.67%)   Thrombocytopenia * 3/60 (5.00%)   Cardiac failure * 1/60 (1.67%)   Cardiac failure acute * 1/60 (1.67%)   Cardiogenic shock * 1/60 (1.67%)   Left ventricular dysfunction * 1/60 (1.67%)   Anal fistula * 1/60 (1.67%)
Secondary_evidence: Adverse Events 1:   Total: 4/26 (15.38%)   Febrile neutropenia * 1/26 (3.85%)   Gastric volvulus * 20/26 (0.00%)   General Malaise * 21/26 (3.85%)   Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)   Acute renal failure * 21/26 (3.85%) Adverse Events 2:   Total: 1/28 (3.57%)   Febrile neutropenia * 0/28 (0.00%)   Gastric volvulus * 21/28 (3.57%)   General Malaise * 20/28 (0.00%)   Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)   Acute renal failure * 20/28 (0.00%)